Media headlines about Tandem Diabetes Care (NASDAQ:TNDM) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 45.7290046987712 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts have commented on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, December 20th. Robert W. Baird restated a “hold” rating and issued a $3.00 price objective on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Wedbush restated an “outperform” rating and issued a $17.00 price objective (down previously from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $11.33.
Shares of Tandem Diabetes Care (TNDM) traded down $0.06 during trading hours on Thursday, hitting $2.48. The stock had a trading volume of 147,300 shares, compared to its average volume of 153,600. Tandem Diabetes Care has a 52-week low of $2.15 and a 52-week high of $30.00. The stock has a market cap of $25.70, a price-to-earnings ratio of -0.13 and a beta of 0.17. The company has a quick ratio of 0.88, a current ratio of 1.90 and a debt-to-equity ratio of -2.70.
In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff bought 285,700 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were purchased at an average price of $3.50 per share, for a total transaction of $999,950.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 20.90% of the company’s stock.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.